Aion Therapeutic Announces Closing of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 6,666,333 units ("Units") at a price of $0.075 per Unit for gross proceeds…

Read now

Follow Microdose to stay up-to-date with the entire psychedelic industry.

Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study

Vancouver, British Columbia--(Newsfile Corp. - February 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming…

Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process

Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has…

Havn Life announces DTC Eligibility of Its Common Shares in the United States

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce today that its common shares are…

Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial

London, United Kingdom--(Newsfile Corp. - February 19, 2021) - Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa's Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential…

Mindset Pharma Added to North American Psychedelics Index

Toronto, Ontario--(Newsfile Corp. - February 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that…

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing…

Pure Extracts and Canada House Wellness Group sign agreement to distribute concentrate products through existing provincial distribution channels

VANCOUVER, British Columbia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) a plant-based extraction company, focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, and Canada…

Track the Horizons Psychedelic Stock Index ETF

Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial

London, United Kingdom--(Newsfile Corp. - February 19, 2021) - Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa's Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential…

Mindset Pharma Added to North American Psychedelics Index

Toronto, Ontario--(Newsfile Corp. - February 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that…

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing…

Pure Extracts and Canada House Wellness Group sign agreement to distribute concentrate products through existing provincial distribution channels

VANCOUVER, British Columbia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) a plant-based extraction company, focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, and Canada…

Tryp Therapeutics Completes $2 Million Strategic Financing

La Jolla, California--(Newsfile Corp. - February 17, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that effective February 16, 2021, it…

Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Technology is Expected to Provide Continuous Monitoring

Ehave, Inc. to leverage data and AI to correlate biomarkers for the identification of psychedelic drug administration as a treatment for Chronic pain, Depression (major and persistent), PTSD, Bipolar disorder, General anxiety, ADHD and Schizophrenia MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) --…

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technology

DENVER, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital health platform and the world's-first telemedicine application…

Psyched Wellness Closes $6,603,000 Bought Deal Private Placement

Toronto, Ontario--(Newsfile Corp. - February 17, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that further to its…

Revive Therapeutics Acquires Unique Psilocybin Assets

TORONTO, Feb. 17, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that, further to its press release dated…

MindMed’s LSD Neutralizer Study Begins

Potential Emergency Off-Switch for Psychedelic Assisted Therapies BASEL, Switzerland, Feb. 17, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced the start of a study for its LSD neutralizer technology intended to shorten…

Mindset Pharma Announces U.S. Listing Application for OTCQB Venture Market

Toronto, Ontario--(Newsfile Corp. - February 17, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTC PINK: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to…

Havn Life Announces Changes to Board Composition and Departure of Ms. Rasode

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), announces the departure of Ms. Barinder Rasode as President and as a director of the Company, effective immediately. The Company also announces that its Chief Executive Officer, Mr. Tim…

Field Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results

Q3 2021 patient services revenues of $316,329 represent a 235% increase over the previous quarter  Field Trip continues to advance development of FT-104, a novel psychedelic molecule with pending patents by accelerating activities in manufacturing and preclinical toxicology to acquire the data…

Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development

Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Dr.…

Cybin Inc. Releases Financial Highlights and Provides Business Update

Successful bought deal offering brings total capital raised to-date to approximately $90 million  Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines  Adelia Therapeutics acquisition expands scientific…

Pure Extracts Agrees to Licensing deal with Taste-T, LLC the US manufacturer of Fireball Cannabis Gummies

VANCOUVER, British Columbia, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased…

Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program

La Jolla, California--(Newsfile Corp. - February 16, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced that Albany Molecular Research ("AMRI")…

Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

TORONTO, Feb. 12, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously…

The Conscious Acquisition Company Announces the 
First Psychedelic Medicine Focused SPACs

Exchange Listing, LLC and The Conscious Fund announce their partnership and the creation of The Conscious Acquisition Company. The new venture is a range of Special Purpose Acquisition Company (SPACs) aimed to create long-term value in psychedelic medicine. The pioneering SPACs will take a thematic…

Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program

TORONTO, Feb. 11, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its cannabinoid…

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

ZUG, Switzerland, Feb. 11, 2021 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic…

Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor

La Jolla, California--(Newsfile Corp. - February 11, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has executed an advisory…

Field Trip Health Ltd. Schedules Third Fiscal Quarter 2021 Financial Results Conference Call for Wednesday, February 17, 2021 at 8:00 am ET

TORONTO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP, FTRP.WT, OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its third fiscal quarter ended December…

Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates

Toronto, Ontario--(Newsfile Corp. - February 10, 2021) -  Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that…

NeonMind Submits Applications to Health Canada for Product Formulas to Support Cognitive and Immune Function and to Fight Stress

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2021) -  NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), announces that through its consumer products division, it submitted on February 2, 2021 four applications to Health Canada's Natural and Non-prescription Health…

Pure Extracts Announces Its First Commercial Sale of CBD Oil on the Wholesale Market

VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic…

Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering

TORONTO, Feb. 09, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that, further to its press releases dated…

Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica

TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce the official opening of the Field Trip Natural Products Limited Research and Development…

Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller

La Jolla, California--(Newsfile Corp. - February 8, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announces it has commenced a collaboration with Dr.…

Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing

Acquisition expands Numinus' presence while improving psychedelic-assisted therapy landscape in Canada VANCOUVER, BC, Feb. 8, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting…

Numinus Engages Native Ads Inc. for Digital Media Services

VANCOUVER, BC, Feb. 5, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce…

Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds

Toronto, Ontario--(Newsfile Corp. - February 5, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a leading drug discovery and development company focused on the development novel next generation psilocybin-inspired medicines and related technologies, is pleased to…

Tryp Therapeutics Announces Strategic Investment of $2,000,000

La Jolla, California--(Newsfile Corp. - February 5, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp") is pleased to announce a non-brokered private placement (the "Placement") of 3,333,333 million units (the "Units") at a price of $0.60 per Unit, to raise gross proceeds of approximately $2.0…

Entheon Biomedical Hires ClearTV Executive as VP of Digital Experience Entertainment Veteran Jonna Birgans to Oversee Digital and VR Content Development

Vancouver, British Columbia--(Newsfile Corp. - February 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Jonna…

Cybin Announces Closing of Upsized Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO–(Official Release)–Cybin Inc. (NEO: CYBN) (“Cybin” or the “Company”), (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, is…

Psyched Wellness Provides Update on Antioxidant and Anti-Inflammatory Study of Muscimol

Toronto, Ontario--(Newsfile Corp. - February 4, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to share an update on the…

Aion Therapeutic Grants Stock Options; Announces Management Change

Toronto, Ontario--(Newsfile Corp. - February 3, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has granted and issued options for the purchase of up to 4,000,000 common shares of the Company to a number of the Company's officers, directors…

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

DENVER, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream…

Pure Extracts Announces Submission for Class 1 Natural Product Number (NPN)

VANCOUVER, British Columbia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic…

Tryp Therapeutics Announces Appointment of Greg McKee as Executive Chairman

La Jolla, California--(Newsfile Corp. - February 3, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, needs is pleased to announce the appointment of Greg McKee…

Psyched Wellness to Participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference

Toronto, Ontario--(Newsfile Corp. - February 2, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushroom derived products, is pleased to…

Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments

Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) -  Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides an update on license…

Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board

La Jolla, California--(Newsfile Corp. - February 2, 2021) - Tryp Therapeutics, a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical needs, is pleased to announce that it has added world renowned psychedelic scientist, Dr. Robin Carhart Harris to…

Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.

Havn Life to supply psychedelic compounds for clinical trials launched by neuroscience and technology leader HealthTech Connex Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of…

Mindset Pharma Retains Corporate Development Advisors

Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has…

Ehave Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression

MIAMI, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, is announcing plans to roll out its ketamine home delivery platform known as KetaDASH. The backbone for KetaDASH will be…

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

DENVER, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream…

Mindset Selects Compounds from Its Third Psilocybin-Inspired Drug Family to Move into in vivo PoC Studies

Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has…

Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Key milestones met in ongoing trials, expanding national footprint, and enhanced research capabilities ensure Numinus' continued growth VANCOUVER, BC, Jan. 29, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a health care and research company developing and…

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

  DENVER, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine…

Field Trip Health Ltd. Common Shares to Trade on the OTCQX Best Market

TORONTO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce its common shares have been approved for trading on the OTCQX® Best Market (“OTCQX”)…

Pure Extracts Announces DTC Eligibility of Its Common Shares in the United States

VANCOUVER, British Columbia, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic…

Ehave Looks to Expand KetaDASH to Palliative Care

MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it is exploring how palliative patients could benefit from its Ketamine home delivery platform, KetaDASH.…

Cybin Included in First Psychedelic Exchange Traded Fund

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, – Cybin Inc. (NEO: CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it is among the select…

Mindset Pharma Announces Listing on the Frankfurt Stock Exchange

Toronto, Ontario--(Newsfile Corp. - January 27, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that its…

Get Bi-Weekly Updates

Subscribe to the Market Insights Report

Each Wednesday and Saturday, we will send you a review of the latest price movements, financial analysis, and original insights on the emerging financial landscape of the psychedelic industry.

  • This field is for validation purposes and should be left unchanged.